Interactions with Dietary Supplements
Coenzyme Q10
In a double-blind trial, individuals with high cholesterol who were treated with lovastatin or pravastatin
(drugs related to atorvastatin) for 18 weeks had a significant reduction in blood levels of
coenzyme Q10 (CoQ10).1 One study found that supplementation with 100 mg of CoQ10
prevented declines in CoQ10 levels when taken with
simvastatin (another HMG-CoA reductase inhibitor drug).2 Many doctors recommend
that people taking HMG-CoA reductase inhibitor drugs such as atorvastatin also supplement with
approximately 100 mg CoQ10 per day, although lower amounts, such as 10–30 mg per day,
might conceivably be effective in preventing the decline in CoQ10 levels.
Magnesium-containing antacids
A magnesium- and aluminum-containing antacid was reported
to interfere with atorvastatin absorption.3 People can avoid this interaction by
taking atorvastatin two hours before or after any aluminum/magnesium-containing antacids. Some
magnesium supplements such as magnesium hydroxide are also antacids.
Niacin
Niacin is the form of vitamin B3 used to lower
cholesterol. Ingestion of large amounts of niacin along with lovastatin (a drug closely related to atorvastatin) or with
atorvastatin itself may cause muscle disorders (myopathy) that can become serious
(rhabdomyolysis).4 5 Such problems appear to be uncommon when HMG-CoA
reductase inhibitors are combined with niacin.6 7 Moreover, concurrent
use of niacin with HMG-CoA reductase inhibitors has been reported to enhance the
cholesterol-lowering effect of the drugs.8 9 Individuals taking
atorvastatin should consult their physician before taking niacin.
Vitamin A
A study of 37 people with high cholesterol treated with diet and HMG-CoA reductase inhibitors
found blood vitamin A levels increased over two years of therapy.10 Until more is
known, people taking HMG-CoA reductase inhibitors, including atorvastatin, should have blood
levels of vitamin A monitored if they intend to supplement vitamin A.
References
1. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum
coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med
1997;18(suppl):S137–44.
2. Bargossi AM, Grossi G, Fiorella PL, et al. Exogenous CoQ10
supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors.
Mol Aspects Med 1994;15(suppl):s187–93.
3. Threlkeld DS, ed. Diuretics and Cardiovasculars, Antihyperlipidemic
Agents, HMG-CoA Reductase Inhibitors. In Facts and Comparisons Drug Information. St.
Louis, MO: Facts and Comparisons, Sep 1998, 172a.
4. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A
reductase inhibitors. Am J Health Syst Pharm 1995;52:1639–45.
5. Yee HS, Fong NT. Atorvastatin in the treatment of primary
hypercholesterolemia and mixed dyslipidemias. Ann Pharmacother
1998;32:1030–43.
6. Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and
niacin in hypercholesterolemia: a preliminary report on safety. Am J Cardiol
1994;73:25D–9D.
7. Jokubaitis LA. Fluvastatin in combination with other lipid-lowering
agents. Br J Clin Pract Suppl 1996;77A:28–32.
8. Davignon J, Roederer G, Montigny M, et al. Comparative efficacy and
safety of pravastatin, Nicotinic acid and the two combined in patients with
hypercholesterolemia. Am J Cardiol 1994;73:339–45.
9. Jacobson TA, Jokubaitis LA, Amorosa LF. Fluvistatin and niacin in
hypercholesterolemia: a preliminary report on gender differences in efficacy. Am J
Med 1994;96(suppl 6A):64S–8S.
10. Muggeo M, Zenti MG, Travia D, et al. Serum retinol levels throughout
2 years of cholesterol-lowering therapy. Metabolism 1995;44:398–403.
11. Radulovic LL, Cilla DD, Posvar EL, et al. Effect of food on the
bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol
1995;35:990–4.
12. Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic
effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic
subjects in the morning and evening. J Clin Pharmacol 1996;36:604–9.
13. Radulovic LL, Cilla DD, Posvar EL, et al. Effect of food on the
bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol
1995;35:990–4.
Copyright © 2004 Healthnotes, Inc. All rights reserved.
www.healthnotes.com
Please read the disclaimer
about the limitations of the information provided here. Do NOT rely solely on the information
in this article.
Learn more about Healthnotes, the company.
Learn more about the authors of Using
Medicines with Vitamins and Herbs
The information presented in Healthnotes is for informational
purposes only. It is based on scientific studies (human, animal, or in vitro),
clinical experience, or traditional usage as cited in each article. The results reported may
not necessarily occur in all individuals. For many of the conditions discussed, treatment with
prescription or over-the-counter medication is also available. Consult your doctor,
practitioner, and/or pharmacist for any health problem and before using any supplements or
before making any changes in prescribed medications. Information expires March 2005.